Topics

Sun Upbeat On IL-23 Prospects In US, Ilumya Faring ‘Reasonably’

14:49 EST 10 Nov 2019 | SCRIP

Sun expects interleukin-23-targeting drugs to stay a preferred treatment option for psoriasis in the US and saw some sales uptick...

      

Related Stories

 

Original Article: Sun Upbeat On IL-23 Prospects In US, Ilumya Faring ‘Reasonably’

NEXT ARTICLE

More From BioPortfolio on "Sun Upbeat On IL-23 Prospects In US, Ilumya Faring ‘Reasonably’"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...